OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Dapagliflozin administration for 1 year promoted kidney enlargement in patient with ADPKD
Shinya Nakatani, Fumiyuki Morioka, Hideki Uedono, et al.
CEN Case Reports (2023) Vol. 13, Iss. 4, pp. 284-289
Open Access | Times Cited: 8
Shinya Nakatani, Fumiyuki Morioka, Hideki Uedono, et al.
CEN Case Reports (2023) Vol. 13, Iss. 4, pp. 284-289
Open Access | Times Cited: 8
Showing 8 citing articles:
KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Olivier Devuyst, Curie Ahn, Thijs R.M. Barten, et al.
Kidney International (2025) Vol. 107, Iss. 2, pp. S1-S239
Open Access | Times Cited: 6
Olivier Devuyst, Curie Ahn, Thijs R.M. Barten, et al.
Kidney International (2025) Vol. 107, Iss. 2, pp. S1-S239
Open Access | Times Cited: 6
Additional renoprotective effect of the SGLT2 inhibitor dapagliflozin in a patient with ADPKD receiving tolvaptan treatment
Shun Minatoguchi, Hiroki Hayashi, Ryosuke Umeda, et al.
CEN Case Reports (2024) Vol. 13, Iss. 5, pp. 419-424
Open Access | Times Cited: 5
Shun Minatoguchi, Hiroki Hayashi, Ryosuke Umeda, et al.
CEN Case Reports (2024) Vol. 13, Iss. 5, pp. 419-424
Open Access | Times Cited: 5
Dapagliflozin treatment in patients with chronic kidney disease associated with autosomal dominant polycystic kidney disease
Masatoshi Yoshimoto, Akinari Sekine, Tatsuya Suwabe, et al.
Clinical Kidney Journal (2024) Vol. 17, Iss. 8
Open Access | Times Cited: 4
Masatoshi Yoshimoto, Akinari Sekine, Tatsuya Suwabe, et al.
Clinical Kidney Journal (2024) Vol. 17, Iss. 8
Open Access | Times Cited: 4
Renoprotective effects of combination therapy with tolvaptan and dapagliflozin in autosomal dominant polycystic kidney disease: a four-case series
Junji Nishida, Mayuko Yamakawa, Shoko Miura, et al.
CEN Case Reports (2025)
Open Access
Junji Nishida, Mayuko Yamakawa, Shoko Miura, et al.
CEN Case Reports (2025)
Open Access
Correlation of HbA1c levels with CT-based body composition biomarkers in diabetes mellitus and metabolic syndrome
Joshua Warner, Glen M. Blake, John W. Garrett, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Joshua Warner, Glen M. Blake, John W. Garrett, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial
Elisabeth Bahlmann-Kroll, Sebastian Häckl, Stefanie D. Krämer, et al.
BMJ Open (2024) Vol. 14, Iss. 12, pp. e088317-e088317
Open Access | Times Cited: 1
Elisabeth Bahlmann-Kroll, Sebastian Häckl, Stefanie D. Krämer, et al.
BMJ Open (2024) Vol. 14, Iss. 12, pp. e088317-e088317
Open Access | Times Cited: 1
Correlation of HbA1c levels with CT-based body composition biomarkers in diabetes mellitus and metabolic syndrome
Joshua Warner, Glen M. Blake, John W. Garrett, et al.
Research Square (Research Square) (2024)
Open Access
Joshua Warner, Glen M. Blake, John W. Garrett, et al.
Research Square (Research Square) (2024)
Open Access
